Vaxart (OTCMKTS:VXRT – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Vaxart to related companies based on the strength of its analyst recommendations, risk, earnings, valuation, profitability, institutional ownership and dividends.
Institutional and Insider Ownership
18.0% of Vaxart shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 2.8% of Vaxart shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Vaxart has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Vaxart’s rivals have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Profitability
This table compares Vaxart and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vaxart | 16.02% | 35.14% | 17.10% |
| Vaxart Competitors | -2,398.26% | -203.62% | -15.08% |
Earnings & Valuation
This table compares Vaxart and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Vaxart | $237.26 million | $16.33 million | 2.77 |
| Vaxart Competitors | $18.73 billion | $3.24 billion | 559.13 |
Vaxart’s rivals have higher revenue and earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a breakdown of current ratings and price targets for Vaxart and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vaxart | 0 | 1 | 0 | 0 | 2.00 |
| Vaxart Competitors | 7845 | 13798 | 25819 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.40%. Given Vaxart’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Vaxart has less favorable growth aspects than its rivals.
Summary
Vaxart rivals beat Vaxart on 9 of the 13 factors compared.
About Vaxart
Vaxart, Inc. is a clinical-stage biotechnology company developing oral vaccines for infectious diseases. Its proprietary platform is designed to deliver vaccine candidates in tablet form and to stimulate immune responses at mucosal surfaces as well as throughout the body. The company’s investigational programs have included vaccines for norovirus, seasonal influenza and COVID-19. These candidates remain in development and are not approved vaccines. Based in South San Francisco, California, Vaxart focuses on research and development and may work with external partners to advance its vaccine programs.
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
